UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported) April 7, 1998
CARTER-WALLACE, INC.
(Exact name of registrant as specified in its charter)
Delaware 1-5910 13-4986583
(State or other juris- (Commission (IRS Employer
diction of incorporation) File Number) Identification No.)
1345 Avenue of the Americas, New York, NY 10105
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: 212-339-5000
No Change
(Former name or former address, if changed since last report)
Page 1 of 3
Item 5 - Other Events
The following is the text of a press release of Carter-Wallace,
Inc., issued on April 7, 1998:
Carter-Wallace, Inc. today announced that, because
the clinical data to date does not support efficacy,
it has terminated its clinical study of the
intravenous use of Taurolin (taurolidine) for sepsis.
Page 2 of 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
CARTER-WALLACE, INC.
(Registrant)
DATED: April 7, 1998 By: /s/Ralph Levine
Ralph Levine
President & Chief
Operating Officer
Page 3 of 3
